Stratégies thérapeutiques du cancer de la prostate résistant à la castration

25 mars 2011

Auteurs : Th. Bessede
Référence : Prog Urol, 2011, 21, S68, suppl. S2


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser


Lebret T., Mejean A. Role of hormonotherapy in the treatment of metastatic prostate cancer Prog Urol 2008 ;  18 : S332-S337
Lebret T., Mejean A. Management of metastatic androgeno-independent prostate cancer Prog Urol 2008 ;  18 : S343-S348
Timsit M.O., Lebret T., Mejean A. Chemotherapy of hormonore-fractory and hormonoresistant metastatic prostate cancer Prog Urol 2008 ;  18 : S365-S375
Smith M.R., Kabbinavar F., Saad F., Hussain A., Gittelman M.C., Bilhartz D.L., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 2005 ;  23 : 2918-2925 [cross-ref]
Malkowicz S.B. The role of diethylstilbestrol in the treatment of prostate cancer Urology 2001 ;  58 : 108-113 [inter-ref]
Scherr D.S., Pitts W.R. The nonsteroidal effects of diethylstilbestrol:the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer J Urol 2003 ;  170 : 1703-1708 [cross-ref]
Byar D.P. VACURG studies of conservative treatment Scand J Urol Nephrol Suppl 1980 ;  55 : 99-102
Smith D.C., Redman B.G., Flaherty L.E., Li L., Strawderman M., Pienta K.J. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer Urology 1998 ;  52 : 257-260 [inter-ref]
Farrugia D., Ansell W., Singh M., Philp T., Chinegwundoh F., Oliver R.T. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy BJU Int 2000 ;  85 : 1069-1073 [cross-ref]
Bagnato A., Natali P.G. Endothelin receptors as novel targets in tumor therapy J Transl Med 2004 ;  2 : 16 [cross-ref]
Villers A., Neuzillet Y., Beuzeboc P. Inhibitors of the receptor A for endothelin-1 Prog Urol 2010 ;  20 : S77-S79 [inter-ref]
James N.D., Caty A., Borre M., Zonnenberg B.A., Beuzeboc P., Morris T., et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic:a double-blind, placebo-controlled, randomised, phase 2 trial Eur Urol 2009 ;  55 : 1112-1123 [cross-ref]
Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer:directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 2005 ;  23 : 8253-8261 [cross-ref]
Attard G., Reid A.H., A’Hern R., Parker C., Oommen N.B., Folkerd E., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 2009 ;  27 : 3742-3748 [cross-ref]
Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009 ;  324 : 787-790 [cross-ref]
Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Lancet 2010 ;  375 : 1437-1446 [cross-ref]

© 2011 
Elsevier Masson SAS. Tous droits réservés.